US Edition
US FDA approves Gilead's twice-yearly injection for HIV prevention
- The U.S. FDA approved Yeztugo, a twice-yearly injectable drug by Gilead Sciences for HIV prevention, on Thursday, June 19, 2025.
- This approval is based on two clinical trials demonstrating that biannual injections provide almost total prevention of HIV infection, showing greater effectiveness compared to daily preventive pills.
- Gilead developed lenacapavir, the drug's generic name, after two decades of research overcoming initial challenges with drug stability and efficacy.
- Greg Millett, who leads public policy efforts at The Foundation for AIDS Research , expressed optimism that this approach could potentially halt HIV transmission, while highlighting that widespread implementation faces significant systemic challenges.
- Despite the approval's promise, experts warn that healthcare cuts and insurance hurdles may slow adoption and limit reach to populations most at risk.
362 Articles
362 Articles
Injection Claimed To Prevent HIV Approved By FDA * 100PercentFedUp.com * by Danielle
The Food and Drug Administration (FDA) approved a twice-yearly injection developed to prevent HIV. The first and only of its kind drug, manufactured by Gilead Sciences, will be sold under the name Yeztugo (lenacapavir). WATCH: #GileadNews: The FDA has approved our injectable HIV-1 prevention medication, making it the first and only twice-yearly #HIV prevention option in the U.S. This approval is helping to usher in the future of prevention as w…
FDA approves first twice-a-year PrEP injectable - Dallas Voice
The U.S. Food and Drug Administration this week approved Gilead Sciences’ twice-a-year shot, lenacapvir, to prevent HIV, Gilead announced on Wednesday, June 18. It is the first and only long-acting injectable approved for pre-exposure prophylaxis at this time. The approval is “the first step in an anticipated global rollout that could protect millions,” according to The Edge Media Network. But it remains unclear how many people in the U.S. and a…
Only two injections per year to prevent infection from the HIV virus, instead of the current preventive therapies that, although effective, provide for the administration of one tablet every day. (ANSA)
HIV prevention injection approved by FDA in medical breakthrough
In a significant development in the global fight against HIV, the US Food and Drug Administration (FDA) has approved the long-acting injection Lenacapavir for the prevention of HIV. Marketed as Yeztugo by pharmaceutical company Gilead Sciences, the drug is administered just twice a year and has shown exceptional effectiveness in clinical trials.
Coverage Details
Bias Distribution
- 66% of the sources are Center
To view factuality data please Upgrade to Premium
